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HIV pre-exposure prophylaxis trials with antiretroviral drugs have been variably successful. Even
trials demonstrating the best efficacy leave room for improvement. Pharmacological data illuminate
several sources of outcome variability, especially the impact of poor adherence, which is critical to
manage PrEP in the clinic and to develop the next generation of PrEP candidates.Biomedical approaches are under study to reduce HIV transmis-
sion in combination with established behavioral interventions.
Though treating HIV-infected persons reduced transmission to
partners by 96% in one prospective trial (Cohen, et al. 2011),
as few as 19% of HIV-infected persons in the US are in long-
term treatment with full viral suppression associated with partner
protection (Gardner, et al. 2011). A complementary approach
prevents HIV infection through pre-exposure prophylaxis
(PrEP) of the susceptible, uninfected person with antiretroviral
drugs. Outcomes in PrEP trials of tenofovir (TFV)-containing reg-
imens vary widely, from 75% protection (relative risk reduction)
to no protection (Baeten, et al., 2012; Van Damme, et al., 2012;
J. Marrazzo et al., 2013, 20th Conference on Retroviruses and
Opportunistic Infections, abstract). Understanding this variation
may optimize PrEPmanagement in the clinic and future random-
ized clinical trials (RCTs). The relationship between pharmacoki-
netics (PK, drug concentration variation in time and anatomic
space) and pharmacodynamics (PD, concentration response)
will be shown to explain much of the variation among RCTs.
Development Challenges
In PrEP drug development, unlike HIV treatment, there is no
biomarker of drug effect in susceptible uninfected individuals
to inform PrEP trial design. Animal models of HIV challenge
have been useful, providing proof of principle, but are limited
to non-HIV viruses or by anatomic and pharmacologic differ-
ences with humans. Ex vivo HIV challenge of colon tissue biopsy
explants from healthy individuals on TFV demonstrates a con-
centration response and surmounts several animal model limita-
tions (Anton, et al., 2012). However, the traumatic biopsy and
in vitro challenge conditions may introduce influential but clini-
cally irrelevant variables. Explant utility awaits validation against
seroconversion events in clinical studies.
EvencapturingPK-PDdata inRCTswith repeatedPKsampling
or tissue biopsy is logistically difficult. As a result, sexual mucosal
tissue, arguably the critical site of infection and PrEP drug action,
hasnotbeenstudiedduringanyphase2B/3RCT.Nonetheless, all
of the PrEP RCTs to date have used sparse sampling of plasma,peripheral blood mononuclear cells (PBMCs), or cervicovaginal
fluid tomeasuredrugconcentrations for correlationwithHIVsero-
conversion. Surprisingly, these accessible nontissue sites yield
useful data to guide PrEP dosing and RCT planning.
Explanatory Concentrations
All PrEP RCTs that demonstrated efficacy also showed better
efficacy with higher drug concentration. In iPrEx (daily TFV diso-
proxil fumarate [TDF]/emtricitabine [FTC] in men who have sex
with men [MSM]), HIV protection increased from 42% in all
participants to 92% in participants with measurable (above
assay quantitative limits) plasma TFV (Grant, et al., 2010). In
the Partners in Prevention (PIP) trial (HIV-discordant heterosexu-
al partners on daily TDF or TDF/FTC), the protection increased
from 67% to 86% in the TDF arm and 75% to 90% in the TFV/
FTC arm when plasma TFV was measurable (Baeten, et al.,
2012). In CDC TDF2 (daily TDF/FTC in heterosexual women
and men), only 50% of seroconverters had measurable plasma
TFV compared to >80% of nonseroconverters (Thigpen, et al.,
2012). The Thai injection drug user (IDU) study (daily TDF/FTC)
reported a 70% risk reduction in participants with measurable
compared to immeasurable plasma TFV (Choopanya, et al.,
2013). By contrast, in FEM-PrEP and VOICE (daily oral TDF or
TDF/FTC in heterosexual women), there was no efficacy and
no plasma TFV concentration response.
Beyond plasma, CAPRISA 004 investigators showed that
womenwith >1,000 ng/ml cervicovaginal fluid TFV concentration
were protected from HIV infection (incidence rate ratio 0.26
compared to placebo), and women below 1,000 ng/ml were
not protected (incidence rate ratio 0.86; Karim, et al., 2011). iPrEx
investigators reported 16 fmol/millions cells as the TFV diphos-
phate (TFV-DP) PBMC concentration associated with 90% pro-
tection (Anderson, et al., 2012). TFV-DP is the active moiety of
TFV phosphorylated intracellularly. For this 90% protective con-
centration to be used as a ‘‘target,’’ a confirmatory study would
be welcomed. Also, the target may not be relevant for hetero-
sexual men and women whose primary site of infection is not
the colon (see below).Cell 155, October 24, 2013 ª2013 Elsevier Inc. 515
Figure 1. Plasma Tenofovir Concentration Response among PrEP
Trials
Relationship of median (IQR) TFV plasma concentration and mean (95% CI)
relative risk reduction are indicated for each PrEP trial (except CAPRISA). Red
arrows pointing to gray circles indicate iPrEx and VOICE gel adjustments
(described in the text). Emax model of adjusted concentration response is
indicated by the green line. Primary transmission risk is indicated by black
(heterosexual), pink (vaginal), blue (MSM), and red (IDU) circles. Study labels
indicate gender and regimen. Gender symbols indicate treated persons (no
parentheses) and partners (in parentheses), with ‘‘+’’ indicating known HIV+
partner and ‘‘?’’ indicating unknown partner status. Regimen is indicated by T
(oral TDF or vaginal TFV), E (FTC), po (daily oral), and gel (daily vaginal).There is also concentration response among the TFV-contain-
ing PrEP trials (Figure 1). The most efficacious trials fall short of
complete protection, but higher median RCT plasma concen-
trations—achievable with consistent daily TDF—likely would
achieve greater efficacy. To optimize PrEP efficacy for an individ-
ual or in a clinical trial setting, understanding the sources of drug
concentration variation in relation to seroconversion is crucial.
Assessing Adherence
The range of median plasma concentrations among oral TFV
RCTs is 70 ng/ml to undetectable (<0.3 ng/ml)—a very large
2.4 log10 difference. Some variation is due to participants taking
their doses at different times of day, resulting in variable time
between the last scheduled daily dose and the clinic TFV blood
collection. However, the expected within-day fluctuations at
steady state on daily oral TFV range from 300 ng/ml peak con-
centrations to 60 ng/ml trough concentrations in plasma—only a
0.7 log10 difference, explaining little of the observed TFV varia-
tion among trials.
Absent evidence of a PK rationale for large inter- and intra-
study concentration difference and the large difference from
expectations, poor and variable adherence becomes the best
explanation. In a study of daily TFV in South African, Ugandan,
and US women, there were no PK differences after an observed
dose among racial or geographic subgroups (Minnis et al., 2013).
However, there were 5-fold differences between US and African
women in predose TFV concentrations, best explained by adher-
ence differences, as there were no PK differences.
The poor adherence suggested by plasma TFV concentrations
is in spite of high degrees of self-reported adherence near 90%516 Cell 155, October 24, 2013 ª2013 Elsevier Inc.or more. In FEM-PrEP and VOICE, less than 40% and 30%,
respectively, of participants had evidence of recent drug use at
study visits based on plasma TFV. In VOICE, 30% of participants
took no TDF in the week prior to any given clinic visit based on
undetectable plasma TFV. Other sample types with far longer
half-lives —PBMC lysates, dried blood spots, and hair—have
less variable daily fluctuations and the capacity to reflect drug-
taking behavior averaged over weeks or months prior to collec-
tion. None of these methods, however, identify short periods of
missed doses that likely affect seroconversion in a trial if con-
current with HIV exposure. Electronic monitoring devices that
record pill container opening get closer to capturing actual
drug-taking events. The combination of drug concentration
and electronic monitoring is being analyzed to model patterns
of adherence and covariates.
The highest median TFV concentration among all PrEP RCTs,
70 ng/ml in PIP, falls at the low end of expected concentra-
tions, inconsistent with daily dosing on average unless at least
80% of participants took their last dose 24 hr before the clinic
visit. If greater numbers took evening doses, thereby increasing
expected concentrations in clinic above 70 ng/ml, adherence es-
timates fall. Low adherence estimates during a trial could trigger
adherence interventions or cessation of enrollment at poorly
adherent sites rather than jeopardizing the entire study. In clinical
practice, low drug concentrations may warrant adherence inter-
ventions. Drug concentrations may also prove useful to test the
efficacy of adherence interventions.
Route of Dosing Impact
Vaginal and rectal dosing of TFV gel (40 mg TFV per dose)
achieves vaginal and rectal tissue homogenate concentrations
of TFV-DP more than 130 and 6–10 times greater, respectively,
than after oral dosing (300 mg TDF) in crossover dosing studies
(Anton, et al., 2012; Hendrix, et al., 2013). If tissue is most rele-
vant to sexual HIV protection, one would expect topical dosing
to outperform oral dosing. That the two RCTs that included
vaginal dosing (CAPRISA 004 and VOICE) achieved among the
lowest levels of efficacy suggests needed investigation of vari-
ables that might set these studies apart, such as coital dosing
(CAPRISA 004), local effects of vaginal dosing, and adherence
(Abdool Karim, et al., 2010; J. Marrazzo et al., 2013, 20th Confer-
ence on Retroviruses and Opportunistic Infections, abstract).
Again, this judgment of underperformance assumes that tissue
concentration is the relevant site of action and may be used as
a pharmacologic frame of reference.
In contrast to tissue concentrations, serum TFV and PBMC
TFV-DP concentrations are far greater after oral dosing—56
and 17 times greater, respectively—in cross-over studies
(Dumond, et al., 2007; Schwartz, et al., 2011; Patterson, et al.,
2011; Hendrix, et al., 2013). These differences must be taken
into account when comparing oral and topical dosing studies,
for example, when using plasma concentration to assess adher-
ence. This is the rationale for the upward adjustment of the
VOICE gel arm in the figure.
Route of Infection
iPrEx efficacy (42% risk reduction) relative to median TFV
plasma concentration (10 ng/ml) does not fall neatly within the
concentration response among heterosexual and IDU popula-
tions studied despite similar daily TDF (±FTC) regimens
(Figure 1). Two potential differences in MSM may explain this.
First, colon has >120 times the vaginal concentrations of tissue
homogenate TFV-DP (Patterson, et al., 2011; Louissaint, et al.,
2013). If tissue is the site of drug action, this effectively shifts
the concentration upward. Second, the 20-fold or more
increased risk of infection from unprotected receptive anal sex
compared to receptive vaginal intercourse effectively moves
the concentration, partly, back down. This adjustment assumes
that higher infection risk is related to greater viral access to sus-
ceptible cells that, therefore, require greater drug concentration
to maintain protective drug-virus ratios. This upward adjustment
brings iPrEx in line with the concentration response relationship
of the other risk groups (Figure 1). This colon advantage, how-
ever, disappears 1 week later in single-dose studies because
of colon-vaginal differences in TFV-DP half-life (Patterson,
et al., 2011; Louissaint, et al., 2013), which suggests proportional
loss of the benefit with less than daily dosing.
Based on samples of rectal fluid after vaginal dosing and cer-
vicovaginal fluid after rectal dosing, direct TFV diffusion between
these two compartments has been observed (Anton, et al., 2012;
Hendrix, et al., 2013). Whether concentrations in the second
compartment without the topical dose are protective awaits
ongoing biopsy studies and clarification of protective concentra-
tions in each tissue.
The figure naively lumps heterosexual men and women, as
PrEP was equally effective in men and women in PIP. Also, there
are insignificant male-female differences in TFV plasma PK after
oral dosing. Unfortunately, without penile or foreskin PK data in
men, one cannot know if potential male-female tissue concen-
tration differences might balance known differences in transmis-
sion risk.
Efficacy and TFV concentrations in the Thai IDU study fall
slightly below (with largely overlapping distributions) the mixed
gender heterosexual studies (PIP, TDF2). CD4+ T cell TFV-DP
concentration in PBMCs fall between concentrations from cells
extracted from colon and vaginal tissue (Louissaint, et al.,
2013). The agreement in protection and susceptible target cell
concentration between heterosexual and IDU populations is a
bit surprising. Given greater viral inoculum, founder virus num-
ber, and frequency of transmission per exposure with blood-
borne IDU infection, one might have anticipated the effective
drug concentration to be higher.
Dose Schedule
Except for coitally-dependent dosing prescribed in CAPRISA
004, all of the PrEP RCTs prescribed daily dosing. No study
directly compared seroconversion between different dose fre-
quencies. Because CAPRISA 004 differed from other studies in
both schedule and route of dosing, it is difficult to link CAPRISA
004 outcomes to other RCTs using plasma concentrations, and it
is excluded from the figure. Expected plasma concentrations are
lower with vaginal dosing, as discussed above. The highly vari-
able and potentially long period between sex-related gel dosing
and clinic blood collections introduces substantial variation and
reduction, respectively, in plasma TFV concentration. More
study is needed to understand why CAPRISA 004 protection isso far below expectations that are based on high vaginal tissue
concentrations with topical compared to oral dosing.
Tentative Targets
One might reduce costs and improve adherence by using PrEP
only during periods of high-risk sexual activity. Because TFV
phosphorylation takes time, the timing of doses before and after
the HIV risk period becomes critical. The iPrEx PBMC TFV-DP
90% efficacious concentration (16 fmol/million cryopreserved
cells, 24–48 fmol/million freshly lysed cells) might be a target
for episodic PrEP in MSM. In healthy volunteers receiving TDF,
PBMCTFV-DP rises gradually, reaches peak 12–24 hr postdose,
is sustained for 3–4 days between 10–20 fmol/million freshly
lysed cells, and then falls logarithmically with 48 hr half-life
(Chen, et al., 2012; Louissaint, et al., 2013). A single TDF dose
cannot reach the 24–48 fmol/million lysed cell target in most
men. Doubling the first dose before sexual exposure—per the
Anrs Ipergay PrEP trial—increases the chance of hitting the iPrEx
target, but only 12–24 hr after dosing. Needed tests of intermit-
tent and episodic PrEP regimens are currently underway.
PD modeling of the typical value from each PrEP trial (except
CAPRISA) crudely estimates the median plasma TFV concentra-
tion associated with 90% protection (EC90) at 105–110 ng/ml
whether using the adjusted plasma concentrations for VOICE
gel and iPrEx or excluding each of them. Because prior dose
time is unobserved and varies in time relative to plasma TFV
sampling, expression of this concentration in adherence terms
is complex. Under most scenarios, the EC90 is achievable only
with daily adherence on average. By comparison, the EC90 in
iPrEx was associated with only two to four average doses per
week (16 fmol/million cryopreserved PBMC TFV-DP, 10 ng/ml
plasma TFV). Pharmacometric modeling with covariates using
all data from these RCTs, not just typical values, is greatly
needed before acting on very tentative estimates.
The additive effect of FTC is unclear, and there are not asmany
multicompartment PK studies as for TFV. No efficacy differences
appear in RCTs comparing TDF and TDF/FTC arms, but the
studies were not powered to pick up modest differences. In
addition to variables discussed above, numerous other variables
may influence PrEP outcomes: partner viral load, HIV exposure
frequency, toxic mucosal effects of topical gel (drug or vehicle)
or lubricants, or concomitant sexually transmitted infections.
The quantitative impact of these variables is either unknown or
difficult to objectively measure in an RCT.
Improving RCT Design
The financial and personnel investment in a PrEP trial is too great
to initiate without the use of the best data at hand. Clinical trial
simulation (CTS) allows trial planners to explore the sensitivity
of various trial designs to influential variables and to compete de-
signs against each other to select optimal designs. CTS for PrEP
requires quantitative models of adherence, pharmacokinetics,
pharmacodynamics, and HIV transmission dynamics. Intercom-
partmental PKmodels and PK-PD linkage models have not been
developed aside from iPrEx, but very rich data sets exist to build
them. Cautious use of animal models and explant challenge
studies may also be helpful. Models describing participant and
study characteristics influencing adherence patterns are criticalCell 155, October 24, 2013 ª2013 Elsevier Inc. 517
to CTS, given the large impact of adherence on PrEP efficacy.
Adherence models can draw upon data from studies with elec-
tronic monitoring systems or pre-/postdose PK sampling using
population PK models, but these data are less plentifully
collected during PrEP trials.
Viral dynamic models have been developed based on in vitro
and HIV treatment studies and then linked to TFV PK data
(from treated populations) to perform simulations of PrEP effi-
cacy and its sensitivity to many of the variables discussed
above—target concentration, adherence, time to protective con-
centrations, and viral inoculums (Duwal, et al., 2012)—many of
which have been confirmed as influential in clinical studies.
One key difference is the EC90, which is >267 fmol/million fresh
lysed cells in the in silico model and 24–48 fmol/million fresh
lysed cells in iPrEx (Duwal, et al., 2012; Anderson, et al., 2012).
Far more clinical data from PrEP RCTs and healthy volunteer
PK studies are also now available to recalibrate parameter esti-
mates in both in silico and clinical models.
Next-Generation PrEP
Combining sparse PK data from heterogeneous PrEP RCTs with
data from more intensely sampled PK studies enables explana-
tion of PrEP outcomes in a more mechanistic manner, enhances
our ability to modify regimens to achieve desired concentration
targets, and provides many of the elements for CTS. As several
new antiretroviral PrEP candidates enter development, the
challenge will be to translate the maturing TFV/FTC knowledge
to other PrEP candidates, to do so earlier in development, and
to better understand nonpharmacological variables so that
our attempts to explain, predict, and optimize PrEP will greatly
improve with the next generation.
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